



# Health Technology Assessment Policy and Methods Review Reference Committee

## Communique – 27 October 2023 meeting

The Health Technology Assessment (HTA) Policy and Methods Review (Review) Reference Committee (Committee) met by video conference on 27 October 2023.

Medicines Australia, HTAnalysts, and Amgen representatives were invited to speak to the Committee. Support staff from the Review Secretariat in the Department of Health and Aged Care (Department) and the probity advisor also attended.

### **What did the Committee discuss?**

#### **Deep Dive: Accelerated Access**

The Committee heard a comprehensive presentation from representatives of Medicines Australia, Amgen, and HTAnalysts on options to streamline submission pathways to improve time to access for patients. Representatives discussed the nature of the submission system, industry perspectives on current challenges, and gave options for areas of reform. The slides presented to the Reference Committee by Medicines Australia are included in the attached document (Attachment A).

The Committee discussed the proposed options with the representatives, with the discussion including the following topics: high-added value therapies; therapeutic groups; proposed legislation; scope of the Review; industry views on complexity of the current submission process; price negotiations; model validation; and managing/accepting uncertainty and risk.

#### **Issues and Options relating to industry presentation on accelerated access**

The Committee discussed the practicality and expected results of implementing options proposed by stakeholder representatives in the previous session.

#### **Update on the ALLG Scientific Meeting**

The Committee heard from Professor Roberts on discussions at the Australasian Leukaemia and Lymphoma Group scientific meeting where he presented an update, on behalf of the Chair, on the work currently engaged by the HTA Review.

#### **Clinical Trials**

The Committee heard a presentation from Ms de Somer on the current state of clinical trials and industry perspectives.

The presentation covered: the current state of phase 3 clinical trials in Australia; timeliness in recruiting patients; the proposal of a national “one-stop shop” agreement between the states

and territories; and proposed methods of incentivising clinical trials, including relevance of Australian research and development to the HTA assessment.

The Committee discussed the details of incentivising clinical trials in Australia, including price negotiations and value propositions.

### **Other Business**

The Committee discussed administrative matters regarding the operation of the Committee.

### **Meeting close and next meeting**

The Committee noted the next meeting will be held on 10 November 2023.